Clinical trial · Observational
Characteristics and Tumor Staging Proposal for Primary Malignant Melanoma of the Esophagus
Characteristics and Tumor Staging Proposal for Primary Malignant Melanoma of the
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Background: Primary malignant melanoma of the esophagus (PMME) is a malignant tumor originating from esophageal melanocytes with a poor prognosis. No international clinical guidelines or tumor staging systems have been proposed for PMME. This study aimed to analyze the clinical characteristics and treatment outcomes of patients with PMME and propose a tumor staging system in PMME. Materials and Methods: The clinical characteristics of 25 patients with PMME at our cancer center were summarized, and 21 patients were enrolled in a pooled analysis with 162 cases (extracted from 74 eligible articles in PubMed) for further survival analysis and proposal of PMME tumor staging.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Primary Malignant Melanoma of the Esophagus | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Overall Survival(OS)
- timeFrame
- From date of disease diagnosis until the date of death from any cause, assessed up to 170 months
- description
- Overall Survival (OS) is a term used in oncology and clinical trials to refer to the length of time from either the date of diagnosis or the start of treatment for a disease, such as cancer, that patients diagnosed with the disease are still alive.
- measure
- Disease-free survival (DFS)
- timeFrame
- From the date of the initial treatments in Sun Yat-sen University Cancer Center to the recurrence of the disease or death due to any cause, assessed up to 170 months
- description
- Disease-free survival (DFS) is defined as the time from randomization to recurrence of tumor or death, and it is typically used in the adjuvant treatment setting.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 23 Years
- Maximum age
- 72 Years
Show eligibility criteria text
Inclusion Criteria: 1. primary malignant melanoma of esophagus confirmed via biopsy; autopsy; endoscopic mucosal resection and dissection and specimen in pathologic diagnosis 2. patients who had been followed up for ≥6 months or reached endpoint event Exclusion Criteria: 1. patients with primary malignant melanoma of esophagus and other esophageal tumors 2. patients without a clear TNM stage or who could not be reassessed using 8th AJCC edition of esophagus and esophagogastric junction cancer staging manual
References
Publications (0)
Data not yet available